Core Viewpoint - Gilead's recent deal is aimed at enhancing its expanding inflammation portfolio [1] Group 1 - The deal is expected to strengthen Gilead's position in the inflammation market [1]

Core Theme - A significant investment theme for 2026 is the focus on dividend stocks, which provide recurring income and stability, although they are not guaranteed investments [1] Company Overview - Bristol Myers Squibb (NYSE: BMY) is highlighted as a leading healthcare company with a current dividend yield of 4.4%, significantly higher than the S&P 500 average of 1.2% [2] - The company has a history of raising its dividend for 17 consecutive years, with a manageable payout ratio of 72% [6] Financial Performance - Last year, Bristol Myers' revenue was flat at $48.2 billion, with a forecast for this year ranging from $46 billion to $47.5 billion [5] Challenges and Risks - The company faces significant challenges due to impending patent cliffs on key drugs like Eliquis and Opdivo, which could lead to increased generic competition and negatively impact revenue and cash flow [4] - There is uncertainty surrounding the company's ability to maintain its dividend, with the possibility of a dividend cut or suspension depending on future performance [7] Investment Sentiment - Despite the attractive dividend yield and historical performance, there is a lack of confidence in Bristol Myers as a stable investment, suggesting that investors may be better off considering index funds that pay dividends instead [6][7]

Core Insights - Novartis has announced the acquisition of Pikavation Therapeutics for $2 billion upfront, potentially rising to $3 billion with milestone payments, to enhance its pipeline in oncology [1] - The acquisition focuses on SNV4818, a pan-mutant-selective PI3Kα inhibitor aimed at treating HR+/HER2- breast cancer and other solid tumors, indicating a strategic move towards precision medicine [1][3] - Despite the potential of SNV4818, Novartis' stock has declined nearly 10% following the announcement, reflecting market skepticism [4] Company Strategy - The acquisition aligns with Novartis' strategy to strengthen its oncology portfolio, particularly in targeting PI3Kα, a well-established driver in HR+/HER2- breast cancer [2] - SNV4818 employs new mutant-selective chemistry to improve tolerability and efficacy, positioning it as a next-generation treatment option [3] Market Context - Novartis currently markets Piqray, a PI3Kα-targeting drug that generated $382 million in revenue last year, although it saw a decline of approximately 15% year-on-year [5] - The competitive landscape includes Eli Lilly's STX-478, which highlights the increasing interest and investment in PI3Kα inhibitors within the pharmaceutical industry [1][5]

Core Insights - Fennec Pharmaceuticals Inc. is set to release its fourth-quarter earnings results on March 24, with analysts expecting earnings of 4 cents per share, a significant improvement from a loss of 6 cents per share in the same quarter last year [1] - The consensus estimate for quarterly revenue is $14.73 million, which represents a substantial increase from $7.92 million a year earlier [1] Recent Developments - On March 16, Fennec Pharmaceuticals announced a settlement agreement that resolves the PEDMARK patent litigation, which positively impacted the stock price, leading to a 1.8% increase to close at $7.45 [2] - Analysts have been actively rating the company, and Benzinga provides access to the latest analyst ratings, allowing readers to sort by various criteria [2]

Market Overview - The trading day ended with optimism as major indices saw gains, with the Dow Jones up 600 points (1.4%), S&P 500 up 75 points (1.2%), and Nasdaq composite up 300 points (1.4%) [6] - The S&P 500 had over 400 names in the green, with all 11 sectors showing positive performance, led by consumer discretionary, which gained approximately 2.5% [7][8] Commodity Prices - Oil prices saw Brent crude below $100 per barrel, with WTI at $88.70, while gold experienced a decline of 2%, marking its ninth consecutive day of losses [3][4] Company Performance - DraftKings and Flutter saw gains of over 1% and 4.4% respectively, following news of bipartisan legislation affecting sports betting [9][10] - Cruise lines, including Carnival and Royal Caribbean, experienced gains of over 6% due to optimism surrounding the geopolitical situation [11][12] - Palantir's shares rose nearly 6.8% as its AI system was set to become an official program for the Pentagon [13] Decliners - Micron shares fell by 4.4% after reporting higher-than-expected capital expenditures [15] - Pfizer's shares hovered lower by about 0.7% after announcing its Lyme vaccine's effectiveness was only 73% [16] - FICO shares dropped by 5.7% following scrutiny from Senator Josh Hawley regarding mortgage credit scoring practices [17] - Estee Lauder's shares fell by 7.7% amid reports of a potential merger with Puig brands [18] Treasury Market - The Treasury market experienced significant volatility, with the two-year yield showing the largest one-day swing since August 1st of the previous year, closing down by about five basis points [20][21]

Group 1 - Pfizer's stock has declined by 25% over the past five years, while the S&P 500 has increased by 68%, leading to a loss of investor confidence in the company's growth potential [1] - The stock has recently started to outperform the S&P 500, attributed to increased market concerns and a shift towards dividend stocks, with Pfizer's dividend yield at 6.4% [2][5] - In 2023, Pfizer's stock experienced a significant drop of 44%, and it has faced declines in previous years, including a 6% drop in 2025 and an 8% drop in 2024 [4] Group 2 - Despite a modest gain of 8% this year, Pfizer's stock remains undervalued with a forward price-to-earnings multiple of just over nine [6] - The company's revenue for the past year was $62.6 billion, reflecting a 2% operational decline from the previous year, indicating stability despite growth concerns [7]

Group 1 - Inclusive Capital Partners is looking to sell approximately 8.5 million shares in Bayer AG, valued at about 327 million euros ($380.17 million) based on the stock's closing price [2][3] - The stake sale is being arranged by JPMorgan Chase, indicating a significant move by the activist investor [2] - Inclusive Capital, led by activist investor Jeff Ubben, took a stake in Bayer in early 2023 and was instrumental in the ousting of former CEO Werner Baumann [3] Group 2 - Current CEO Bill Anderson, who took over in June 2023, is overhauling Bayer's management structure but has suspended a strategic review that could have led to a breakup of the company [4] - Bayer recently issued a 2026 earnings target range that fell below market expectations, highlighting challenges related to costly litigation and substantial financial debt [4]

Core Viewpoint - The investigation by Levi & Korsinsky, LLP focuses on allegations against Inovio Pharmaceuticals, Inc. regarding false or misleading statements made during the Class Period from October 10, 2023, to December 26, 2025 [1] Group 1: Legal Framework - The action is based on the efficient market hypothesis, which posits that all publicly available information is quickly reflected in stock prices [2] - The fraud-on-the-market doctrine suggests that false statements made by defendants are incorporated into the stock price, allowing plaintiffs to rely on the market price without proving individual reliance on each misstatement [3][8] - The presumption of fraud-on-the-market facilitates class treatment under Federal Rule of Civil Procedure 23, asserting that common legal and factual questions prevail over individual ones [5] Group 2: Allegations Against Inovio - Plaintiffs argue that Inovio's stock traded on NASDAQ, an efficient market, and was subject to analysis by multiple analysts [4] - Allegations include misrepresentations regarding device manufacturing and FDA regulatory pathways, which purportedly inflated INO's stock price during the Class Period [4] Group 3: Investor Recovery - Securities class actions enable investors to pursue claims that may be too costly to bring individually, supporting recovery in cases of alleged fraud [6] - The firm has a strong track record in handling complex fraud-on-the-market cases and has been recognized among the top firms in this area for seven consecutive years [7]

Core Viewpoint - A class action securities lawsuit has been filed against Corcept Therapeutics Incorporated, alleging securities fraud that affected investors between October 31, 2024, and December 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who were adversely affected by alleged securities fraud during the specified period [2]. - The complaint states that the defendants made false statements regarding their interactions with the FDA and the approval prospects of relacorilant, which were misleading given the FDA's concerns about the drug's effectiveness and the design of the GRACE study [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until April 21, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. for allegedly making false statements and failing to disclose material facts regarding its Phase 3 clinical trial for its product DCCR, which has led to significant financial losses for investors [2][5][6]. Company Overview - Soleno Therapeutics, Inc. is a pharmaceutical company based in Redwood City, California, focused on developing therapies for rare diseases. Its primary product is diazoxide choline extended-release tablets (DCCR), aimed at treating hyperphagia in individuals with Prader-Willi syndrome (PWS) [4]. Lawsuit Details - The lawsuit was filed on behalf of investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025. The case is registered in the United States District Court for the Northern District of California [2][6]. - Investors have until May 5, 2026, to file for lead plaintiff status in the class action [2][8]. Allegations - The complaint alleges that Soleno's executives made materially false and misleading statements regarding the safety and commercial viability of DCCR, including: 1. Downplaying safety concerns related to excess fluid retention in clinical trial participants [5]. 2. Misrepresenting the risks associated with DCCR, which could lead to adverse events post-commercial launch [5]. 3. Resulting in a decline in stock price by over 26% following the release of a critical report by Scorpion Capital [6][7]. Investor Actions - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for recovery options at no cost. They can either seek to be appointed as lead plaintiffs or remain as absent class members [3][8].